|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
ATE145428T1
(de)
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
IE920716A1
(en)
|
1991-03-07 |
1992-09-09 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
CA2128511C
(en)
|
1992-01-23 |
2006-11-07 |
Andreas Pluckthun |
Monomeric and dimeric antibody-fragment fusion proteins
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
CA2135408A1
(en)
|
1992-05-08 |
1993-11-25 |
Peter C. Keck |
Chimeric multivalent protein analogues and methods of use thereof
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
DE69334275D1
(de)
|
1992-08-21 |
2009-05-20 |
Univ Bruxelles |
Immunoglobuline ohne Leichtkette
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
CA2145278C
(en)
|
1992-09-25 |
2009-03-10 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
|
CA2126967A1
(en)
|
1992-11-04 |
1994-05-11 |
Anna M. Wu |
Novel antibody construct
|
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
|
ES2185705T3
(es)
|
1994-05-02 |
2003-05-01 |
Bernd Groner |
Proteina bifuncional, preparacion y uso.
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
JP3659261B2
(ja)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
組換体タンパク質の多機能性複合体への標的化ヘテロ結合
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
AU708339B2
(en)
|
1995-02-24 |
1999-08-05 |
General Hospital Corporation, The |
Redirection of cellular immunity by receptor chimeras
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
WO1996037621A2
(en)
|
1995-05-23 |
1996-11-28 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Multimeric proteins
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
WO1997038102A1
(en)
|
1996-04-04 |
1997-10-16 |
Unilever Plc |
Multivalent and multispecific antigen-binding protein
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
DK0920505T3
(da)
|
1996-08-16 |
2008-09-08 |
Schering Corp |
Pattedyrcelleoverfladeantigener og tilhörende reagenser
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
EP0937095A4
(en)
|
1996-10-25 |
1999-12-22 |
Cell Genesys Inc |
TARGETED CYTOLYSIS OF CANCER CELLS
|
|
US6323322B1
(en)
|
1997-04-30 |
2001-11-27 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
AU736707B2
(en)
|
1997-06-11 |
2001-08-02 |
Anaphore, Inc. |
Trimerising module
|
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ,インコーポレイティド |
人工抗体ポリペプチド
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
|
CA2308114A1
(en)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
DK1027439T3
(da)
|
1997-10-27 |
2010-05-10 |
Bac Ip Bv |
Multivalente antigenbindende proteiner
|
|
EP1049787B1
(en)
|
1998-01-23 |
2004-11-24 |
Vlaams Interuniversitair Instituut voor Biotechnologie |
Multipurpose antibody derivatives
|
|
JP2002502607A
(ja)
|
1998-02-09 |
2002-01-29 |
ジェネンテク・インコーポレイテッド |
新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
|
|
HUP9900956A2
(hu)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
ES2207278T3
(es)
|
1998-07-28 |
2004-05-16 |
Micromet Ag |
Heterominicuerpos.
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
|
JP2002541845A
(ja)
|
1999-04-16 |
2002-12-10 |
セルテック セラピューティックス リミテッド |
合成膜貫通成分
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
ATE376837T1
(de)
|
1999-07-12 |
2007-11-15 |
Genentech Inc |
Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
EP1235842A4
(en)
|
1999-10-15 |
2003-04-23 |
Univ Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
HK1052372A1
(zh)
|
2000-02-24 |
2003-09-11 |
Xcyte Therapies, Inc. |
细胞的同步刺激和富集
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
AU2001264946A1
(en)
|
2000-05-24 |
2001-12-03 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
EP1309705B1
(en)
|
2000-07-25 |
2012-02-15 |
Immunomedics Inc. |
Multivalent target binding protein
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
CN1308447C
(zh)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
低分子化的激动剂抗体
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20030171546A1
(en)
|
2001-04-30 |
2003-09-11 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
JP4303105B2
(ja)
|
2001-06-28 |
2009-07-29 |
ドマンティス リミテッド |
二重特異性リガンドとその利用
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
AU2002319544B2
(en)
|
2001-08-10 |
2008-07-10 |
Aberdeen University |
Antigen binding domains from fish
|
|
ATE346866T1
(de)
|
2001-09-14 |
2006-12-15 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, tandem-fv- antikörper
|
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
|
US20030211078A1
(en)
|
2001-12-07 |
2003-11-13 |
Heavner George A. |
Pseudo-antibody constructs
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
EP1500665B1
(en)
|
2002-04-15 |
2011-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
METHODS FOR CONSTRUCTING scDb LIBRARIES
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
|
US20050003403A1
(en)
|
2003-04-22 |
2005-01-06 |
Rossi Edmund A. |
Polyvalent protein complex
|
|
AU2004244626A1
(en)
|
2003-05-23 |
2004-12-09 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
|
US7700097B2
(en)
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
|
CA2531118C
(en)
|
2003-07-01 |
2013-01-08 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
US8198020B2
(en)
|
2003-08-22 |
2012-06-12 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
EP1786918A4
(en)
|
2004-07-17 |
2009-02-11 |
Imclone Systems Inc |
NEW BISPECIFIC ANTIBODY TETRAVALENT
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
|
EP3530321A1
(en)
|
2004-12-10 |
2019-08-28 |
Peter MacCallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
CA2604032C
(en)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1757622B1
(en)
|
2005-08-26 |
2009-12-23 |
PLS Design GmbH |
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
EP1962961B1
(en)
|
2005-11-29 |
2013-01-09 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
|
WO2007133822A1
(en)
|
2006-01-19 |
2007-11-22 |
Genzyme Corporation |
Gitr antibodies for the treatment of cancer
|
|
CA2638794A1
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
|
EA015992B1
(ru)
|
2006-03-17 |
2012-01-30 |
Байоджен Айдек Эмэй Инк. |
Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
|
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
AU2007285763B2
(en)
|
2006-08-18 |
2011-12-15 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
|
US20100105136A1
(en)
|
2006-10-09 |
2010-04-29 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
WO2008140477A2
(en)
|
2006-11-02 |
2008-11-20 |
Capon Daniel J |
Hybrid immunoglobulins with moving parts
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
EP2626372B1
(en)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
CA2706425A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
TW200944231A
(en)
|
2007-11-30 |
2009-11-01 |
Glaxo Group Ltd |
Antigen-binding constructs
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
US10059923B2
(en)
|
2008-01-30 |
2018-08-28 |
Memorial Sloan Kettering Cancer Center |
Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
|
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
|
JP2011526794A
(ja)
|
2008-07-02 |
2011-10-20 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
TGF−βアンタゴニスト多重標的結合性分子
|
|
CA2735456C
(en)
|
2008-08-26 |
2021-11-16 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
JPWO2010030002A1
(ja)
|
2008-09-12 |
2012-02-02 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
|
EP2389443B1
(en)
|
2009-01-23 |
2018-11-14 |
Roger Williams Hospital |
Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
|
|
CA2753158A1
(en)
|
2009-02-23 |
2010-08-26 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
|
CN102421801B
(zh)
|
2009-03-10 |
2016-03-16 |
比奥根Ma公司 |
抗-bcma抗体
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
IN2015DN02826A
(cg-RX-API-DMAC7.html)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープCity of Hope |
形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
CA2791975C
(en)
|
2010-02-04 |
2021-02-09 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CA2816379A1
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JP5897035B2
(ja)
|
2010-12-14 |
2016-03-30 |
ユニバーシティ オブ メリーランド,ボルチモア |
汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
|
|
JP2014509841A
(ja)
|
2011-01-18 |
2014-04-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌を治療するための組成物および方法
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
ES2785081T3
(es)
|
2011-04-01 |
2020-10-05 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
|
|
EP2694640B1
(en)
|
2011-04-08 |
2017-10-18 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
EP3459560B1
(en)
|
2011-04-08 |
2021-02-24 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
EP2714737A1
(en)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
CA2842798C
(en)
|
2011-07-25 |
2021-02-23 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
MX2014001222A
(es)
|
2011-07-29 |
2014-09-15 |
Univ Pennsylvania |
Receptores coestimuladores de cambio.
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
EP3692794A1
(en)
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
JP6267644B2
(ja)
|
2011-10-20 |
2018-01-24 |
アメリカ合衆国 |
抗cd22キメラ抗原受容体
|
|
IN2014CN03887A
(cg-RX-API-DMAC7.html)
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
BR112014020502A2
(pt)
|
2012-02-22 |
2019-09-24 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
EP2817330B1
(en)
|
2012-02-22 |
2020-07-08 |
The Trustees of the University of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
AU2013246443B2
(en)
|
2012-04-11 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
IN2014MN02293A
(cg-RX-API-DMAC7.html)
|
2012-04-20 |
2015-08-07 |
Emergent Product Dev Seattle |
|
|
PL4019041T3
(pl)
|
2012-07-13 |
2023-05-08 |
The Trustees Of The University Of Pennsylvania |
Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
|
|
MX382772B
(es)
|
2012-07-13 |
2025-03-11 |
Univ Pennsylvania |
Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
|
|
KR20210149195A
(ko)
|
2012-07-13 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
형질도입된 t 세포의 투여 적합성을 평가하는 방법
|
|
EP2872617A4
(en)
|
2012-07-13 |
2015-12-09 |
Univ Pennsylvania |
EPITOP SPREADING IN CONNECTION WITH CAR T CELLS
|
|
IN2014DN10889A
(cg-RX-API-DMAC7.html)
|
2012-07-13 |
2015-09-11 |
Univ Pennsylvania |
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
EP2711418B1
(en)
|
2012-09-25 |
2017-08-23 |
Miltenyi Biotec GmbH |
Method for polyclonal stimulation of T cells by flexible nanomatrices
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP2914628A1
(en)
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Bcmaに対する抗体の選択のための方法
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
US10525075B2
(en)
|
2013-02-22 |
2020-01-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds, compositions, methods, and kits relating to telomere extension
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
KR20240164967A
(ko)
|
2014-02-04 |
2024-11-21 |
카이트 파마 인코포레이티드 |
B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
|
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
WO2015164759A2
(en)
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Mnd promoter chimeric antigen receptors
|
|
CN106456670B
(zh)
|
2014-04-25 |
2020-01-07 |
蓝鸟生物公司 |
制备过继性细胞疗法的改善方法
|
|
BR112016024546A2
(pt)
|
2014-04-30 |
2018-01-23 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
|
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
RS61406B1
(sr)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio Inc |
Poboljšane kompozicije t ćelija
|
|
EP3194585A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Sortase molecules and uses thereof
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
|
AU2015292744C1
(en)
*
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
EP3172231B1
(en)
|
2014-07-24 |
2021-05-05 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
US20170239294A1
(en)
|
2014-10-15 |
2017-08-24 |
Novartis Ag |
Compositions and methods for treating b-lymphoid malignancies
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
CN113698497A
(zh)
|
2014-12-05 |
2021-11-26 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
|
HRP20210582T1
(hr)
|
2014-12-05 |
2021-09-03 |
Memorial Sloan Kettering Cancer Center |
Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
|
|
US10383929B2
(en)
|
2014-12-12 |
2019-08-20 |
Bluebird Bio, Inc. |
BCMA chimeric antigen receptors
|
|
HRP20240357T1
(hr)
*
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
RU2751362C2
(ru)
|
2014-12-29 |
2021-07-13 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US10647778B2
(en)
|
2015-02-09 |
2020-05-12 |
University Of Florida Research Foundation, Incorporated |
Bi-specific chimeric antigen receptor and uses thereof
|
|
EP3270960A4
(en)
|
2015-03-20 |
2018-08-08 |
Bluebird Bio, Inc. |
Vector formulations
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
HUE057285T2
(hu)
|
2015-04-13 |
2022-04-28 |
Pfizer |
Terápiás ellenanyagok és alkalmazásaik
|
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向b細胞成熟抗原之嵌合型抗原受體類
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
JP2018524373A
(ja)
|
2015-07-15 |
2018-08-30 |
ザイムワークス,インコーポレイテッド |
薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
TWI811023B
(zh)
|
2015-08-17 |
2023-08-01 |
美商健生生物科技公司 |
抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
CA2999070A1
(en)
|
2015-09-17 |
2017-03-23 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
CA3009852A1
(en)
|
2015-12-28 |
2017-07-06 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20180099768A
(ko)
|
2015-12-30 |
2018-09-05 |
노파르티스 아게 |
증진된 효능을 갖는 면역 이펙터 세포 요법
|
|
US11090334B2
(en)
|
2016-01-29 |
2021-08-17 |
Med Manor Organics (P) Ltd. |
Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
SG11201807489PA
(en)
*
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018059549A1
(en)
|
2016-09-30 |
2018-04-05 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
RU2019133286A
(ru)
|
2017-03-22 |
2021-04-22 |
Новартис Аг |
Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN118853581A
(zh)
*
|
2017-06-21 |
2024-10-29 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019084288A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
WO2019099639A1
(en)
|
2017-11-15 |
2019-05-23 |
Navartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
MX2020005651A
(es)
*
|
2017-11-30 |
2020-10-28 |
Novartis Ag |
Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US20200061113A1
(en)
|
2018-04-12 |
2020-02-27 |
Novartis Ag |
Chimeric antigen receptor therapy characterization assays and uses thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20200085869A1
(en)
|
2018-05-16 |
2020-03-19 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor therapies
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
SI3844267T1
(sl)
|
2018-08-31 |
2025-10-30 |
Novartis Ag |
Postopki izdelave celic, ki izražajo receptorje himernega antigena
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Cd19及びcd22キメラ抗原受容体及びその使用
|
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
|
JP2023516008A
(ja)
|
2020-02-27 |
2023-04-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|